Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;32(10):2074-2086.
doi: 10.1002/jbmr.3175. Epub 2017 Jun 15.

Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin Expression by Osteoclasts

Affiliations
Free article

Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin Expression by Osteoclasts

Masanori Koide et al. J Bone Miner Res. 2017 Oct.
Free article

Abstract

Bone formation is coupled to bone resorption throughout life. However, the coupling mechanisms are not fully elucidated. Using Tnfrsf11b-deficient (OPG-/- ) mice, in which bone formation is clearly coupled to bone resorption, we found here that osteoclasts suppress the expression of sclerostin, a Wnt antagonist, thereby promoting bone formation. Wnt/β-catenin signals were higher in OPG-/- and RANKL-transgenic mice with a low level of sclerostin. Conditioned medium from osteoclast cultures (Ocl-CM) suppressed sclerostin expression in UMR106 cells and osteocyte cultures. In vitro experiments revealed that osteoclasts secreted leukemia inhibitory factor (LIF) and inhibited sclerostin expression. Anti-RANKL antibodies, antiresorptive agents, suppressed LIF expression and increased sclerostin expression, thereby reducing bone formation in OPG-/- mice. Taken together, osteoclast-derived LIF regulates bone turnover through sclerostin expression. Thus, LIF represents a target for improving the prolonged suppression of bone turnover by antiresorptive agents. © 2017 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.

Keywords: MOLECULAR PATHWAYS-REMODELING; OSTEOBLASTS; OSTEOCLASTS; OSTEOCYTES; WNT/BETA-CATENIN/LRPS.

PubMed Disclaimer

MeSH terms